Biotech Companies By Enterprise Value
LargestBiggest EarnersMost ProfitableMost LiquidHighly LeveragedTop DividendsCapital-HeavyHighest ValuationLargest Workforce
Current Valuation
| Current Valuation | Efficiency | Market Risk | Exp Return | ||||
|---|---|---|---|---|---|---|---|
| 1 | REGN | Regeneron Pharmaceuticals | (0.06) | 2.00 | (0.11) | ||
| 2 | SMMT | Summit Therapeutics PLC | 0.04 | 5.37 | 0.23 | ||
| 3 | BNTX | BioNTech SE | (0.08) | 3.15 | (0.24) | ||
| 4 | CPRX | Catalyst Pharmaceuticals | 0.07 | 3.20 | 0.24 | ||
| 5 | TARS | Tarsus Pharmaceuticals | (0.02) | 3.48 | (0.08) | ||
| 6 | APGE | Apogee Therapeutics, Common | (0.04) | 4.35 | (0.19) | ||
| 7 | CNTA | Centessa Pharmaceuticals PLC | (0.03) | 3.57 | (0.11) | ||
| 8 | ARDX | Ardelyx | 0.06 | 4.53 | 0.29 | ||
| 9 | SYRE | Spyre Therapeutics | (0.10) | 3.63 | (0.36) | ||
| 10 | CMRX | Chimerix | 0.21 | 9.73 | 2.05 | ||
| 11 | VALN | Valneva SE ADR | 0.21 | 5.21 | 1.08 | ||
| 12 | DNA | Ginkgo Bioworks Holdings | (0.03) | 7.05 | (0.19) | ||
| 13 | MNMD | Mind Medicine | 0.01 | 5.82 | 0.08 | ||
| 14 | AARD | Aardvark Therapeutics, Common | (0.14) | 7.42 | (1.08) | ||
| 15 | GNFT | Genfit | (0.01) | 3.30 | (0.03) | ||
| 16 | ABCL | Abcellera Biologics | (0.04) | 4.61 | (0.19) | ||
| 17 | TELO | Telomir Pharmaceuticals, Common | 0.02 | 5.68 | 0.12 | ||
| 18 | SLS | Sellas Life Sciences | 0.09 | 7.65 | 0.72 | ||
| 19 | INBX | Inhibrx | 0.01 | 3.41 | 0.04 | ||
| 20 | IBIO | iBio, Common Stock | 0.19 | 7.00 | 1.33 |
The analysis above is based on a 90-day investment horizon and a default level of risk. Use the Portfolio Analyzer to fine-tune all your assumptions. Check your current assumptions here.
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents. Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.